SalioGen Therapeutics (Series B)
Funding Details
- Awarder
- Inbox
- Date Award
- January 05, 2022
- Vertical
- Genetic Medicine
- Funding URL
- View Funding Page
- Funding Amount:
- $115,000,000
Company Info
- Founders
- Ray Tabibiazar
- Company Description
- SalioGen Therapeutics has launched Gene Coding, a genetic medicine platform, to develop durable, broadly applicable genetic medicines, using its Exact DNA Integration Technology (EDITTM) platform. EDIT is based on the novel mammal-derived genomic engineering tool, for use in potentially curative genetic medicines.
- Market
- Inherited Diseases
- Location
- Cambridge, MA, USA
- Coinvestors
- Cystic Fibrosis Foundation, D1 Capital Partners, EPIQ Capital Group, Fidelity Management & Research Company, GordonMD Global Investments, PBM Capital Group, RD Fund, Symbiosis, T. Rowe Price Associates